The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2025 | Long-term follow-up of ECWM-1: dexamethasone, rituximab, and cyclophosphamide +/- bortezomib in WM
Meletios Dimopoulos, MD, Kapodistrian University of Athens School of Medicine, Athens, Greece, shares long-term follow-up from the ECWM-1 trial (NCT01788020) of dexamethasone, rituximab, and cyclophosphamide with or without bortezomib in previously untreated Waldenström’s macroglobulinemia (WM). Prof. Dimopoulos reports that deeper responses were observed when bortezomib was added. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
This is a prospective randomized study in previously untreated patients with Waldenstrom’s macroglobulinemia who were randomized to receive a combination of dexamethasone, rituximab and cyclophosphamide with or without bortezomib. We reported the long-term follow-up data which showed similar progression-free survival and overall survival, deeper responses though when bortezomib was added. We conclude that the dexamethasone, rituximab, cyclophosphamide combination is an active treatment for these patients...
This is a prospective randomized study in previously untreated patients with Waldenstrom’s macroglobulinemia who were randomized to receive a combination of dexamethasone, rituximab and cyclophosphamide with or without bortezomib. We reported the long-term follow-up data which showed similar progression-free survival and overall survival, deeper responses though when bortezomib was added. We conclude that the dexamethasone, rituximab, cyclophosphamide combination is an active treatment for these patients.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
